Shares of Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) are going to reverse split before the market opens on Tuesday, November 24th. The 1-25 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, November 23rd.
Co-Diagnostics Price Performance
Shares of Co-Diagnostics stock traded down $0.04 on Friday, reaching $0.13. The company had a trading volume of 1,140,217 shares, compared to its average volume of 5,645,839. The firm’s 50-day moving average price is $0.72 and its two-hundred day moving average price is $2.03. Co-Diagnostics has a 1 year low of $0.13 and a 1 year high of $13.54.
Co-Diagnostics (NASDAQ:CODX – Get Free Report) last released its earnings results on Tuesday, November 10th. The company reported ($1.01) earnings per share for the quarter, beating the consensus estimate of ($1.25) by $0.24. The firm had revenue of $0.28 million for the quarter, compared to the consensus estimate of $0.17 million. Co-Diagnostics had a negative return on equity of 322.92% and a negative net margin of 5,530.54%.
Wall Street Analyst Weigh In
Several research analysts have commented on the stock. Weiss Ratings lowered shares of Co-Diagnostics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 11th. Maxim Group raised shares of Co-Diagnostics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 18th. Finally, Wall Street Zen upgraded shares of Co-Diagnostics from a “sell” rating to a “hold” rating in a report on Saturday, August 22nd. One investment analyst has rated the stock with a Strong Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus target price of $45.00.
View Our Latest Report on CODX
Hedge Funds Weigh In On Co-Diagnostics
A hedge fund recently bought a new stake in Co-Diagnostics stock. Susquehanna International Group LLP acquired a new stake in Co-Diagnostics, Inc. (NASDAQ:CODX – Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 31,239 shares of the company’s stock, valued at approximately $97,000. Susquehanna International Group LLP owned about 0.85% of Co-Diagnostics as of its most recent SEC filing. 14.99% of the stock is owned by institutional investors and hedge funds.
About Co-Diagnostics
Co-Diagnostics, Inc. is a molecular diagnostics company that develops technologies and tests for detecting infectious diseases. Based in Salt Lake City, Utah, the company’s work centers on its proprietary CoPrimer technology, used to design assays for polymerase chain reaction (PCR) testing. Its products include PCR-based diagnostic tests and related instruments, including the Co-Dx PCR platform. The company has developed tests for a range of infectious diseases, with product availability and regulatory status varying by market.
Further Reading
- Five stocks we like better than Co-Diagnostics
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Co-Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Co-Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
